Amendment: SEC Form F-1/A filed by NewGenIvf Group Limited
$NIVF
Misc Health and Biotechnology Services
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
3 - NewGenIvf Group Ltd (0001981662) (Issuer)
BANGKOK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that Zacks Small-Cap Research ("Zacks") has initiated equity research coverage on the Company. The full equity research report is available on the Zacks website here. About NewGenNewGenIVF Group is a tech-forward, diversified, multi-jurisdictional high-growth entity capitalizing on emerging opportunities across real estate development, digital asset innov
An agreement signed between NewGen and BNW will establish a joint venture to develop NewGen's recently acquired plot of land in Ras Al Khaimah's Beach District, UAE Feasibility studies indicate potential net returns for NewGen of up to US$67 million BANGKOK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has established a new joint venture dedicated to the development of its strategic plot of land in Ras Al Khaimah's Beach District, UAE. The joint venture marks a significant milestone in Ne
Valuation Report from Big Four Global Accounting Firm Sets Fair Value of Acquired IP at US$17.9 Million and Boosts NAV per share by about US$8.9 Acquisition Will Aid NewGen's Transition From IVF Services Provider to Technology-driven Innovator BANGKOK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has received an independent valuation report (the "Report") from a Big Four global accounting firm of its recently acquired advanced cytometry intellectual property (the "IP"), the acquisition of
F-1/A - NewGenIvf Group Ltd (0001981662) (Filer)
6-K - NewGenIvf Group Ltd (0001981662) (Filer)
F-1 - NewGenIvf Group Ltd (0001981662) (Filer)
SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)
SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)
SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)
Company Granted Request to Continue its Listing on NasdaqAppoints Thorain Ko to Lead Business Development Initiatives BANGKOK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to specific conditions. Additionally, the Company announced the appointment of Mr. Thorain Ko as Business Development Director to drive its expansion initiatives. Nasdaq Listing UpdateThe Pane